相关实验视频

Updated: Jun 22, 2025

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

林古伊朱干 (Linggui Zhugan) 开改善了高葡萄糖诱导的足细胞自

Yuan-Yuan Wang¹, Jian Qin², Ru-Lan Zhang¹

¹Department of Traditional Chinese Medicine, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510080, China.

Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih

|July 2, 2024

概括

林珠香 (Linggui Zhugan Decoction,简称LGZGD) 针对其对高葡萄糖诱导的细胞自的作用进行了研究. 通过调节关键蛋白质表达,LGZGD治疗减少了亡并增强了细胞的自,为糖尿病病提供了潜在的治疗益处.

科学领域:

科和中国传统医学
细胞和分子生物学细胞和分子生物学
糖尿病并发症研究研究糖尿病并发症

背景情况:

糖尿病病是糖尿病的一个主要并发症,其特点是细胞损伤和功能障碍.
足细胞自在维持足细胞平衡和功能方面发挥着至关重要的作用.
高水平的葡萄糖会诱导细胞自,从而导致糖尿病病变的发生.

研究的目的:

研究Linggui Zhugan Decoction (LGZGD) 对高葡萄糖诱导的细胞自的治疗潜力.
阐明 LGZGD 影响 podocyte 行为和自的潜在分子机制.

主要方法:

通过使用高葡萄糖治疗的MPC5和AB8/13细胞建立了体外糖尿病病细胞模型.
给治疗的 podocytes 用不同的剂量含有 LGZGD 的血清.
通过Transwell,CCK8,流细胞测量,电子显微镜和西布洛特评估了细胞增殖,迁移,亡,细胞周期,自细胞形成和蛋白质表达 (Beclin-1,Atg5,LC3II/I,P62).

主要成果:

治疗LGZGD,特别是中剂量治疗,恢复了高葡萄糖处理的 podocytes 中的增殖和迁移.
中等剂量的LGZGD显著降低了细胞亡,并改变了细胞的细胞周期进展.
LGZGD干预调节了自细胞形成,并逆转了高葡萄糖诱导的Beclin-1,Atg5,LC3II/I和P62蛋白的上调.

结论:

林朱干 (Linggui Zhugan Decoction,简称LGZGD) 证明了对高葡萄糖诱导的细胞损伤的保护作用.
通过调节Beclin-1/LC3II/I/Atg5信号通路,LGZGD可以增强细胞的自.
作为治疗糖尿病病的治疗剂,LGZGD具有前景.

关键词:

林古伊朱根 (Linggui Zhugan) 蒸煮剂:一种制的饮料.灭症 (apoptosis) 是一种死亡的过程.自自是自的过程.糖尿病性脏病糖尿病脏病这是一个podocyte.

更多相关视频

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

Evaluating Autophagy Levels in Two Different Pancreatic Cell Models Using LC3 Immunofluorescence

Evaluating Autophagy Levels in Two Different Pancreatic Cell Models Using LC3 Immunofluorescence

Published on: April 28, 2023

相关概念视频

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Glucose Absorption Into the Small Intestine

Glucose Absorption Into the Small Intestine

Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and...

Hormones Regulating Blood Glucose

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...

Hypoglycemia and Glucagon

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...